Management of lower-risk myelodysplastic syndromes: the art and evidence.
about
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.Combination strategies in myelodysplastic syndromes.The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots.
P2860
Management of lower-risk myelodysplastic syndromes: the art and evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of lower-risk myelodysplastic syndromes: the art and evidence.
@en
Management of lower-risk myelodysplastic syndromes: the art and evidence.
@nl
type
label
Management of lower-risk myelodysplastic syndromes: the art and evidence.
@en
Management of lower-risk myelodysplastic syndromes: the art and evidence.
@nl
prefLabel
Management of lower-risk myelodysplastic syndromes: the art and evidence.
@en
Management of lower-risk myelodysplastic syndromes: the art and evidence.
@nl
P2860
P1476
Management of lower-risk myelodysplastic syndromes: the art and evidence
@en
P2093
Mikkael A Sekeres
Rami S Komrokji
P2860
P2888
P304
P356
10.1007/S11899-011-0086-X
P50
P577
2011-06-01T00:00:00Z